@ARTICLE{
author={Van Cutsem Eric,Hidalgo Manuel,Bazin Igor,Canon Jean-Luc,Poddubskaya Elena,Manojlovic Nebojsa S,Milella Michele,Radenkovic Dejan V,Verslype Chris,Guo Wei,Damstrup Lars,Hammel Pascal},
year={2015},
title={Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={33},
number={3},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={McCubrey James A,Steelman Linda S,Chappell William H,Abrams Stephen L,Montalto Giuseppe,Cervello Melchiorre,Nicoletti Ferdinando,Fagone Paolo,Malaponte Graziella,Mazzarino Maria C,Candido Saverio,Libra Massimo,Baesecke Joerg,Mijatovic Sanja A,Maksimovic-Ivanic Danijela D,Milella Michele,Tafuri Agostino,Cocco Lucio,Evangelisti Camilla,Chiarini Francesca,Martelli Alberto M},
year={2012},
title={Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.},
journal={ONCOTARGET},
volume={3},
number={9},
pages={954-987},
document_type={Article},
}